BioSpace News Archive

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) (“the Company” or “RegeneRx”), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that it has completed a $500,000 convertible debt financing. The funds will be used for operations while awaiting completion of its phas

- Agreement resolves DOJ investigations into past marketing practices - Settlement funds primarily directed to state, local and tribal governments for opioid crisis abatement purposes - Agreement brings Purdue closer to its ultimate goal of delivering more than $10 billion in value to address the opioid crisis

C-Path, NORD, FDA and more come together to showcase the importance of data sharing in rare disease drug development

Reference is made to the stock exchange announcement by Nordic Nanovector ASA (the “Company”) on 23 and 30 September 2020 where the Company announced the successful completion of a private placement raising gross proceeds of approximately NOK 231 million (the “Private Placement”) and that the board of directors would consider to

Genesprint Group Ltd, a Hong Kong based testing company founded by Paul Tam, Dr. Sherman Fung, Dr. Chi C. Wong, and Infrawear, LLC, the distributor for Genesprint Group’s COVID-19 tests, are now releasing a COVID-19 Rapid Antigen (AG) throat and mouth swab test on the European market.

PLOS Medicine joins growing evidence of safe use of ibuprofen/Advil for COVID-19 symptoms

Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage response (DDR), in particular against rare or resistant cancers, today announced a new milestone in the clinical development of AsiDNA™ with the treatment of the first patient in the Revocan1 phase 1b/2 study designed to evaluate the effect of AsiDNA™

Hancock Jaffe Laboratories, Inc., a developer of medical devices that restore cardiac and vascular health, announced that the ninth VenoValve patient in HJLI’s first-in-human, clinical study has successfully reached the one-year milestone.

Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced today it will be presenting new scientific research at the American College of Rheumatology’s (ACR) first virtual annual meeting, ACR Convergence 2020.

Align Technology, Inc. announced the introduction of Invisalign G8 with SmartForce Aligner Activation, the latest of the company’s biomechanics innovations.